All Industry Workshops take place on Tuesday, Oct. 20 from 1:30-2:30pm. Instructions will be included on the Nexus 2020 Virtual platform.

Industry Workshops provide an opportunity for AMCP corporate members (commercial organizations) to showcase their latest drug therapies, technologies, and a wealth of products and services affecting professionals working in managed care pharmacy.*

Grab your lunch and join an Industry Workshop for the latest in cutting edge research and the latest in drug therapies.

Materials presented in workshops may be promotional and concentrate on a specific product, service, or therapeutic area. Therefore, these presentations are considered promotional and do not offer continuing education credit.

Real-World Evidence: What Does it Mean for the Payer?

Sponsored by Sanofi 


Health plans & PBMs are faced with navigating an increasing number of therapies to treat Type 2 diabetes, while challenged by therapeutic inertia and low rates of medication adherence by patients.  These factors contribute to prolonged periods of hyperglycemia/hypoglycemia leading to increased risk of patients developing diabetes-related complications.  The program will Recognize the importance of data beyond that generated in randomized control trials (RCTs), including real-world data.  We will discuss differences between RCTs and real-world studies.  Finally, we will describe common study design methods and sources of real world evidence (RWE) while focusing on the role of basal insulins in addressing the challenges facing clinicians and patients in achieving glucose control through real world data analysis.


Ron Preblick, PharmD, MPH
Sr. Director, Global Business Partner, General Medicines, Health Economics & Value Assessment (HEVA) / Global Market Access

Laura Wilson, PharmD
Outcomes Liaison Associate Director, General Medicines Division Sanofi

State of the Science in Oncology: The Era of Antibody Drug Conjugates

Sponsored by Seagan


In this wave of innovation in Oncology, antibody-drug conjugates (ADCs) continue to improve outcomes for patients with cancer. With the proven ADC technology platform leading the way of cutting-edge cancer research, improvements to the science and technology have led to increased development and approval of newer ADCs. Scientific advancements have also led to the potential of combining ADCs with treatments such as immunotherapy to further improve outcomes. This session will provide an overview of the evolving Oncology landscape, discuss the state of ADC technology, and highlight FDA-approved and novel ADCs on the horizon. Following the presentation, a panel comprised of diverse key decision makers in the US healthcare system will discuss their perspectives of ADCs and the value of targeted therapies in Oncology.


Rebecca Borgert, Pharm.D. BCOP
Senior Director, Oncology Clinical Strategy and Innovation
Magellan Rx Management

Cindy McDonald-Everett
Vice President, Global Value, Access, and Pricing Seattle Genetics

Nilanjan Ghosh, MD, PhD
Chief, Lymphoma Division & Associate Director, Clinical Trials Levine Cancer Institute
Atrium Health
Clinical Associate Professor of Medicine

Timothy Chiu, PharmD, BCPS
Pharmacist Evidence Analyst & Strategist – Oncology
Drug Intelligence and Strategy
Kaiser Permanente

* Industry Workshops may include preapproved information exchange content. Subject to federal laws and regulations, attendance at PIE sessions is restricted to payors, formulary committee, or other similar entity representatives with knowledge and expertise in the area of health care economic analysis, carrying out responsibilities for the selection of drugs for coverage or reimbursement. For more information, visit our website.